A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti Pd-L1 Antibody) In Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy versus Chemotherapy Alone In Patients with Operable Triple-Negative Breast Cancer

  • Harris, Marion (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/18/SVH/104
NMA SSA Reference Number: SSA/40252/MonH-2019-180463(v1)
Monash Health Ref: RES-19-0000-529X
Effective start/end date13/08/1912/08/24


  • clinical trial
  • treatment efficacy
  • phase 3 study
  • breast cancer